This study is looking at a treatment called stereotactic ablative radiotherapy (SABR) for people with oligometastatic cancer. This means you have a solid tumor that has spread to a few other places (up to 10). SABR is a focused radiation treatment that delivers a strong dose to the tumor while protecting healthy tissues. Researchers want to see if adding SABR to standard care helps people live longer without their cancer getting worse, compared to standard care alone. You may be able to join if you are at least 18 years old and your doctor thinks you are healthy enough for both standard treatments and SABR. The study will measure how long people live without their cancer progressing over two years. The current recruitment status is unclear.

Study design

This is a randomized study with 300 participants. Participants will be randomly assigned to receive either SABR plus standard care, or standard care alone.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how long participants live without their cancer progressing for at least 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.